Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Public ClinicalTrials.gov record NCT06371417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
Study identification
- NCT ID
- NCT06371417
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 144 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2024 (Actual)
- Primary completion
- Mar 31, 2027 (Estimated)
- Completion
- Jun 30, 2027 (Estimated)
- Last update posted
- Jul 22, 2026
2024 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California-Irvine | Orange | California | 92868 | Recruiting |
| Johns Hopkins University | Baltimore | Maryland | 21224 | Recruiting |
| Northwell Health, LLC PRIME | Lake Success | New York | 11042 | Withdrawn |
| Hospital for Special Surgery | New York | New York | 10021 | Withdrawn |
| Universtity of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Recruiting |
| Ohio State University | Columbus | Ohio | 43203 | Withdrawn |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| University of Pennsylvania, Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Amarillo Center for Clinical Research | Amarillo | Texas | 79124 | Withdrawn |
| Austin Neuromuscular Center | Austin | Texas | 78759 | Recruiting |
| Nerve and Muscle Center of Texas | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06371417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06371417 live on ClinicalTrials.gov.